Current Report Filing (8-k)
November 16 2021 - 8:54AM
Edgar (US Regulatory)
0001583771
false
0001583771
2021-11-16
2021-11-16
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities
Exchange Act of 1934
Date of Report (Date of earliest event reported):
November 16, 2021
Hepion
Pharmaceuticals, Inc.
(Exact name of registrant as specified in
its charter)
Delaware
|
|
001-36856
|
|
46-2783806
|
(State or other jurisdiction
|
|
(Commission
|
|
IRS Employer
|
of incorporation or organization)
|
|
File Number)
|
|
Identification No.)
|
399 Thornall Street, First Floor
Edison, NJ 08837
(Address of principal executive offices)
Registrant’s telephone number, including
area code: (732) 902-4000
(Former name or former address, if changed
since last report)
Securities registered pursuant to Section 12(b) of
the Act:
Title of each class:
|
|
Trading Symbol(s)
|
|
Name of each exchange on which registered:
|
Common Stock
|
|
HEPA
|
|
Nasdaq Capital Market
|
Check the appropriate box below if the
Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
¨ Written communication
pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
¨ Soliciting material
pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
¨ Pre-commencement communications
pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
¨ Pre-commencement communications
pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Indicate by check mark whether the
registrant is an emerging growth company as defined in as defined in Rule 405 of the Securities Act of 1933 (§230.405 of
this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company x
If an emerging growth company, indicate by check
mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting
standards provided pursuant to Section 13(a) of the Exchange Act.
On November
16, 2021, Hepion Pharmaceuticals, Inc. issued a press release announcing results of a nonclinical research study showing that
CRV431 significantly decreased the growth of liver tumors in a mouse model of liver cancer. A copy of the press release is furnished as
Exhibit 99.1 to this Form 8-K.
|
Item 9.01
|
Financial Statements and Exhibits
|
(d) Exhibits
SIGNATURE
Pursuant to the requirements
of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto
duly authorized.
Dated: November 16, 2021
|
HEPION PHARMACEUTICALS, INC.
|
|
|
|
|
|
By:
|
/s/ Robert Foster
|
|
Robert Foster
|
|
Chief Executive Officer
|
Hepion Pharmaceuticals (PK) (USOTC:CTRVP)
Historical Stock Chart
From Jul 2024 to Aug 2024
Hepion Pharmaceuticals (PK) (USOTC:CTRVP)
Historical Stock Chart
From Aug 2023 to Aug 2024